1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)

P Barthelemy,C Thibault,E Voog,J-C Eymard,A Ravaud,A Flechon,C Abraham Jaillon,W Hilgers,S Le Moulec,M Chasseray,D Pouessel,Y.E Amela,V Lorgis,E Nicolas,E Kazan,G Denechere,M-N Solbes,P Lambert,Y Loriot

doi:10.1016/j.annonc.2022.07.1835

1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)

P Barthelemy, C Thibault + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1835

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: University of Bordeaux, Institut Claudius Regaud

#Maintenance Treatment In Patients #Metastatic Urothelial Carcinoma + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

In the JAVELIN Bladder 100 trial, patients with la/mUC that had not progressed after 1L platinum-based chemotherapy (CTx) had significantly prolonged overall survival (OS) with avelumab 1L maintenance + best supportive care (BSC) vs BSC only. In the AVENANCE study (NCT04822350), we investigated efficacy and safety in patients with la/muC treated with avelumab 1L maintenance in France.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.